Hypertrophic osteoarthropathy: A palindrome with a pathogenic connotation

Current Opinion in Rheumatology

Volumn 20, Issue 1, 2008, Pages 88-91

  Martinez Lavin, Manuel ^a   Vargas, Angélica ^a   Rivera Viñas, Miguel ^a  

^a INSTITUTO NACIONAL DE CARDIOLOGÍA IGNACIO CHÁVEZ   (Mexico)

Author keywords

Digital clubbing; Hypertrophic osteoarthropathy; Myelofibrosis; Pamidronate; POEMS syndrome; Vascular endothelial growth factor

Indexed keywords

ANTIBIOTIC AGENT; BISPHOSPHONIC ACID DERIVATIVE; CYTOKINE; OCTREOTIDE; PAMIDRONIC ACID; VASCULOTROPIN;

ANKYLOSING SPONDYLITIS; ARTERY GRAFT; CLINICAL FEATURE; CROHN DISEASE; DISEASE COURSE; GRAFT INFECTION; HUMAN; HYPERTROPHIC OSTEOARTHROPATHY; MYELOFIBROSIS; PATENT DUCTUS ARTERIOSUS; PATHOGENESIS; POEMS SYNDROME; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW;

BONE DENSITY CONSERVATION AGENTS; CROHN DISEASE; DIPHOSPHONATES; DUCTUS ARTERIOSUS, PATENT; HUMANS; MYELOFIBROSIS; OSTEOARTHROPATHY, PRIMARY HYPERTROPHIC; OSTEOARTHROPATHY, SECONDARY HYPERTROPHIC; POEMS SYNDROME; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 40349113150     PISSN: 10408711     EISSN: None     Source Type: Journal    
DOI: 10.1097/BOR.0b013e3282f14a5a     Document Type: Review

References (36)

1. Martinez-Lavin M. Exploring the cause of the oldest clinical sign of medicine: finger clubbing. Semin Arthritis Rheum 2007; 36:380-385. A comprehensive review of the literature on the pathogenesis of digital clubbing.
2. Towler DA. Vascular biology and bone formation: hints from HIF. J Clin Invest 2007; 117:1477-1480. VEGF has emerged as the prototypic osteogenic-angiogenic coupling factor.
3. Silveira L, Martínez-Lavín M, Pineda C, et al. Vascular endothelial growth factor in hypertrophic osteoarthropathy. Clin Exp Rheumatol 2000; 18:57-62.
4. Olan F, Portela M, Navarro C, et al. Circulating vascular endothelial growth factor concentrations in a case of pulmonary hypertrophic osteoarthropathy. Correlation with disease activity. J Rheumatol 2004; 31:614-616.
5. Atkinson S, Fox SB. Vascular endothelial growth factor (VEGF)-A and platelet-derived growth factor (PDGF) play a central role in the pathogenesis of digital clubbing. J Pathol 2004; 203:721-728.
6. Alonso-Bartolome P, Martinez-Taboada VM, Pina T, et al. Hypertrophic osteoarthropathy secondary to vascular prosthesis infection: report of 3 cases and review of the literature. Medicine (Baltimore) 2006; 85:183-191. Comprehensive review of this serious and potentially treatable type of HOA.
7. Shinjo SK, Borba EF, Goncalves CR, Levy-Neto M. Ankylosing spondylitis in a patient with primary hypertrophic osteoarthropathy. J Clin Rheumatol 2007; 13:175.
8. Forslund T, Nyberg A, Janne S, Viljanen B. Hypertrophic osteoarthropathy and familial digital clubbing in a patient with surgical closed ductus arteriosus Botalli. Scand J Rheumatol 1987; 16:371-373.
9. Martinez-Lavin M, Pineda C, Navarro C, et al. Primary hypertrophic osteoarthropathy: another heritable disorder associated with patent ductus arteriosus. Pediatr Cardiol 1993; 14:181-182.
10. Levin SE, Harrisberg JR, Govendrageloo K. Familial primary hypertrophic osteoarthropathy in association with congenital cardiac disease. Cardiol Young 2002; 12:304-307.
11. Williams B, Ling JT, Leight L, McGaff C. Patent ductus arteriosus and osteoarthropathy. Arch Intern Med 1963; 111:346-350.
12. Compton RF, Sandborn WJ, Yang H, et al. A new syndrome of Crohn's disease and pachydermoperiostosis in a family. Gastroenterology 1997; 112:241-249.
13. Shim YW, Suh JS. Primary hypertrophic osteoarthropathy accompanied by Crohn's disease: a case report. Yonsei Med J 1997; 38:319-322.
14. Kitis G, Thompson H, Allan RN. Finger clubbing in inflammatory bowel disease: its prevalence and pathogenesis. Br Med J 1979; 2:825-828.
15. Metz EN, Dowell A. Bone marrow failure in hypertrophic osteoarthropathy. Arch Intern Med 1965; 116:759-764.
16. Venencie PY, Boffa GA, Delmas PD, et al. Pachydermoperiostosis with gastric hypertrophy, anemia, and increased serum bone Gla-protein levels. Arch Dermatol 1988; 124:1831-1834.
17. Tanaka H, Maehama S, Imanaka F, et al. Pachydermoperiostosis with myelofibrosis and anemia: report of a case of anemia of multifactorial causes and its improvement with steroid pulse and iron therapy. Jpn J Med 1991; 30:73-80.
18. Fontenay-Roupie M, Dupuy E, Berrou E, et al. Increased proliferation of bone marrow-derived fibroblasts in primitive hypertrophic osteoarthropathy with severe myelofibrosis. Blood 1995; 85:3229-3238.
19. John B, Subhash H, Thomas K. Case of myelofibrosis with hypertrophic osteoarthropathy: the role of platelet-derived growth factor in pathogenesis. N Z Med J 2004; 117:U853.
20. Bachmeyer C, Blum L, Cadranel JF, Delfraissy JF. Myelofibrosis in a patient with pachydermoperiostosis. Clin Exp Dermatol 2005; 30:646-648.
21. Mason BA, Kressel BR, Cashdollar MR, et al. Periostitis associated with myelofibrosis. Cancer 1979; 43:1568-1571.
22. Yu JS, Greenway G, Resnick D. Myelofibrosis associated with prominent periosteal bone apposition. Report of two cases. Clin Imaging 1994; 18:89-92.
23. Walia M, Mehta R, Paul P, et al. Idiopathic myelofibrosis with generalized periostitis in a 4-year-old girl. J Pediatr Hematol Oncol 2005; 27:278-282.
24. Martínez-Lavín M, Vargas AS, Cabré J, et al. Features of hypertrophic osteoarthropathy in patients with POEMS syndrome. A metaanalysis. J Rheumatol 1997; 24:2267-2268.
25. Sartoris DJ, Pate D, Haghighi P, et al. Plasma-cell dyscrasia with polyneuropathy, organomegaly, endocrinopathy, M-protein, and skin changes: the POEMS syndrome. Distinctive radiographic abnormalities. Radiology 1981; 140:17-22.
26. Steurer M, Zoller H, Augustin F, et al. Increased angiogenesis in chronic idiopathic myelofibrosis: vascular endothelial growth factor as a prominent angiogenic factor. Hum Pathol 2007; 38:1057-1064. Bone marrow specimens from 55 patients with myelofibrosis showed increased VEGF expression.
27. Di Sabatino A, Ciccocioppo R, Armellini E, et al. Serum bFGF and VEGF correlate respectively with bowel wall thickness and intramural blood flow in Crohn's disease. Inflamm Bowel Dis 2004; 10:573-577.
28. Watanabe O, Maruyama I, Arimura K, et al. Overproduction of vascular endothelial growth factor/vascular permeability factor is causative in Crow-Fukase (POEMS) syndrome. Muscle Nerve 1998; 21:1390-1397.
29. Suzuma T, Sakurai T, Yoshimura G. Pamidronate-induced remission of pain associated with hypertrophic pulmonary osteoarthropathy in chemoendocrine therapy-refractory inoperable metastatic breast carcinoma. Anti-Cancer Drugs 2001; 12:731-734.
30. Garske LA, Bell SC. Pamidronate results in symptom control of hypertrophic pulmonary osteoarthropathy in cystic fibrosis. Chest 2002; 121:1363-1364.
31. Bhansali S, Singh R, Sriraam M, Bhadada S. Pachydermoperiostitis and bisphosphonates. J Assoc Physicians India 2006; 54:340.
32. Guyot-Drouot MH, Solau-Gervais E, Cortet B, et al. Rheumatologic manifestations of pachydermoperiostosis and preliminary experience with bisphosphonates. J Rheumatol 2000; 27:2418-2423.
33. Amital H, Applbaum YH, Vasiliev L, Rubinow A. Hypertrophic pulmonary osteoarthropathy: control of pain and symptoms with pamidronate. Clin Rheumatol 2004; 23:330-332.
34. Angel-Moreno Maroto A, Martinez-Quintana E, Suarez-Castellano L, Perez-Arellano JL. Painful hypertrophic osteoarthropathy successfully treated with octreotide. The pathogenetic role of vascular endothelial growth factor (VEGF). Rheumatology (Oxford) 2005; 44:1326-1327.
35. Santini D, Vincenzi B, Avvisati G, et al. Pamidronate induces modifications of circulating angiogenetic factors in cancer patients. Clin Cancer Res 2002; 8:1080-1084.
36. Santini D, Vincenzi B, Dicuonzo G, et al. Zoledronic acid induces significant and long-lasting modifications of circulating angiogenic factors in cancer patients. Clin Cancer Res 2003; 9:2893-2897.